U.S. Biotech Stock News

NYSE:CRGY
NYSE:CRGYOil and Gas

Crescent Energy (CRGY) Is Up 11.8% After Return To Profitability And Royalty Cash Flow Launch – Has The Bull Case Changed?

Crescent Energy Company recently reported its fourth-quarter and full-year 2025 results, showing revenue of US$865.05 million for the quarter versus US$875.29 million a year earlier and a swing to full-year net income of US$132.91 million from a prior year net loss. Beyond the headline profitability shift, Crescent executed nearly US$5.00 billion of 2025 transactions, cut drilling and completion costs by 15%, and launched Crescent Royalties, which is already contributing US$160.00 million in...
NYSE:BV
NYSE:BVCommercial Services

BrightView Deepens The Villages Ties With Larger Golf Role And Expertise

BrightView Holdings (NYSE:BV) has expanded its partnership with The Villages, one of the largest master-planned communities in the US. The agreement includes a major increase in the number of golf courses managed by BrightView. The company has also added an expert agronomist to its leadership team to support the expanded scope of work. This combination of operational growth and added expertise represents a material update to BrightView's service footprint. BrightView focuses on commercial...
NYSE:SYK
NYSE:SYKMedical Equipment

What Stryker (SYK)'s Synchfix EVT Adolescent Ankle Device Launch Means For Shareholders

In February 2026, Stryker launched Synchfix EVT, a next-generation flexible syndesmotic fixation device designed to simplify ankle surgery while stabilizing syndesmotic disruptions, and it is the first flexible ankle syndesmotic fixation device cleared for adolescent use. By integrating suture tensioning into an all-in-one, award-winning system that allows one-handed deployment, Synchfix EVT could meaningfully influence surgeon preference and procedure workflows in trauma and sports-related...
NasdaqGS:ENSG
NasdaqGS:ENSGHealthcare

Assessing Ensign Group (ENSG) Valuation After Strong Recent Share Price Momentum

Ensign Group (ENSG) has drawn investor attention after a period of strong share price moves, with the stock up about 25% over the past month and roughly 17% in the past 3 months. See our latest analysis for Ensign Group. Those short term share price moves sit within a wider pattern, with a year to date share price return of 23.14% and a 1 year total shareholder return of 66.10%, suggesting momentum has been building rather than fading. If strong recent gains in healthcare operators have your...
NasdaqGS:BPOP
NasdaqGS:BPOPBanks

How Popular’s Dividend And EPS Outperformance At Popular (BPOP) Has Changed Its Investment Story

Popular, Inc. recently declared a quarterly cash dividend of US$0.75 per share on its common stock, payable on April 1, 2026 to shareholders of record as of March 18, 2026. This payout follows a period in which Popular’s adjusted earnings per share outpaced revenue growth, supported by expanding net interest margins and share repurchases that lifted per-share results. Next, we’ll explore how the stronger-than-expected fourth-quarter earnings underpin Popular’s existing investment narrative...
NasdaqGS:MLYS
NasdaqGS:MLYSBiotechs

A Look At Mineralys Therapeutics (MLYS) Valuation As Lorundrostat Progress Shapes Investor Optimism

Mineralys Therapeutics (MLYS) has drawn fresh attention as investors react to progress on its lead candidate lorundrostat, with upcoming clinical data and a potential New Drug Application in 2026 influencing sentiment around the stock. See our latest analysis for Mineralys Therapeutics. At a share price of US$29.26, Mineralys has recently seen pressure, with a 30 day share price return of 5.28% decline and a 90 day share price return of 25.26% decline. However, the 1 year total shareholder...
NYSE:WMK
NYSE:WMKConsumer Retailing

Why Weis Markets (WMK) Is Down 7.8% After Delaying Its Annual 10-K Filing - And What's Next

In late February 2026, Weis Markets, Inc. disclosed that it would be unable to file its next Form 10-K annual report with the SEC by the required deadline. This kind of filing delay can raise questions about a company’s financial reporting processes or internal controls, making the disclosure particularly important for investors monitoring corporate governance. We’ll now examine how the delayed 10-K filing shapes Weis Markets’ investment narrative, including implications for confidence in...
NasdaqGS:WTW
NasdaqGS:WTWInsurance

How Investors Are Reacting To Willis Towers Watson (WTW) Dividend Hike And New Digital Infrastructure Push

In late February 2026, Willis Towers Watson launched its Global Digital Infrastructure Group, a cross-functional team focused on end-to-end risk solutions for data center and digital infrastructure clients, and its board approved a regular quarterly cash dividend of US$0.96 per share for the quarter ended 31 December 2025, a 4% increase from the prior quarter, payable in mid-April 2026. These moves underline Willis Towers Watson’s effort to deepen its role in emerging digital infrastructure...
NYSE:JLL
NYSE:JLLReal Estate

A Look At Jones Lang LaSalle (JLL) Valuation After Strong Full Year 2025 Earnings Results

Jones Lang LaSalle (JLL) stock is in focus after the company released fourth quarter and full year 2025 results, reporting higher sales, net income, and earnings per share compared with the previous year. See our latest analysis for Jones Lang LaSalle. Despite the stronger full year earnings and ongoing share repurchases, including 256,300 shares bought back in the final quarter of 2025, Jones Lang LaSalle’s recent 30 day share price return decline of 11.84% and year to date decline of 6.04%...
NasdaqGM:ODD
NasdaqGM:ODDPersonal Products

Oddity Tech (ODD) Is Down 60.6% After Forecasting 30% Q1 2026 Revenue Decline - What's Changed

In February 2026, Oddity Tech reported fourth-quarter 2025 sales of US$152.73 million and net income of US$5.88 million, alongside full-year 2025 sales of US$809.84 million and net income of US$110.75 million, while completing a US$47 million buyback of 1,250,000 shares previously announced in June 2024. At the same time, management guided to an approximately 30% year-over-year revenue decline for the first quarter of 2026 due to higher acquisition costs, highlighting a short-term...
NYSE:BKD
NYSE:BKDHealthcare

Is Brookdale’s 2025 Losses, Debt Burden, And AYAL Exit Altering The Investment Case For BKD?

Brookdale Senior Living Inc. reported fourth-quarter 2025 revenue of US$754.09 million and a net loss of US$39.96 million, while full-year 2025 revenue reached US$3.19 billion with a net loss of US$262.69 million, alongside continued participation in major investor conferences. An interesting angle is that, despite higher annual revenue and a reduced quarterly loss, Brookdale’s full-year net loss and ongoing debt concerns coincided with AYAL Capital Advisors fully exiting its US$6.45 million...
NYSE:KNTK
NYSE:KNTKOil and Gas

How Stronger EPS And Kings Landing Progress At Kinetik Holdings (KNTK) Has Changed Its Investment Story

Kinetik Holdings Inc. recently reported fourth-quarter 2025 revenue of US$430.42 million and net income of US$416.70 million, with full-year 2025 revenue of US$1.76 billion and net income of US$525.93 million, marking a sharp jump in earnings per share from continuing operations versus 2024. Alongside these results, Kinetik highlighted progress on projects such as the Kings Landing sour-gas conversion and the Barilla Draw acquisition, while outlining a 2026 “rebuilding” mandate focused on...
NYSE:BKSY
NYSE:BKSYProfessional Services

A Look At BlackSky Technology (BKSY) Valuation As Gen 3 Contracts And Earnings Trends Gain Attention

BlackSky Technology (BKSY) is back in focus after securing more than US$240 million in primarily international Gen 3 satellite contracts, expanding its imaging capacity and pairing that with narrower losses and higher gross margins. See our latest analysis for BlackSky Technology. The recent contract wins and Gen 3 launches come against a mixed price backdrop, with a 14.59% 1 month share price decline and 9.46% year to date share price loss. However, a 46.01% 1 year total shareholder return...
NYSE:ENOV
NYSE:ENOVMedical Equipment

A Look At Enovis (ENOV) Valuation After Earnings Beat And Higher 2026 Profit Guidance

Enovis (ENOV) is back in focus after its latest earnings report paired a large non cash goodwill impairment with adjusted earnings per share above analyst estimates and a profit outlook that topped market expectations. See our latest analysis for Enovis. The strong 7 day share price return of 13.6% and 30 day share price return of 15.56% following Enovis' earnings and guidance update sits against a weaker backdrop. The 90 day share price return is 13.31% and the 1 year total shareholder...
NYSE:AAT
NYSE:AATREITs

How Insider Buying After Mixed Q4 Results At American Assets Trust (AAT) Has Changed Its Investment Story

In recent weeks, American Assets Trust's Executive Chairman Ernest S. Rady bought over US$212,000 of company stock across two transactions, lifting his indirect holdings to more than 8.1 million shares, shortly after the REIT posted mixed fourth-quarter 2025 results with earnings per share below forecasts but revenue ahead of expectations. These insider purchases come as commercial real estate sentiment weakens and interest rates remain elevated, suggesting leadership sees the portfolio’s...
NasdaqGS:ACGL
NasdaqGS:ACGLInsurance

How Arch Capital Group’s Preferred Dividend And AI Push At ACGL Has Changed Its Investment Story

Arch Capital Group recently declared quarterly dividends on its 13,200,000 Series F and 20,000,000 Series G non-cumulative preferred depositary shares, with payments scheduled for March 31, 2026 to holders of record as of March 15, 2026, subject to Bermuda law requirements and potential Board adjustments. This preferred dividend decision comes as Arch Capital’s latest filings highlight strong underwriting and investment outcomes, the integration of Allianz’s U.S. Middle Market P&C business,...
NYSE:LNG
NYSE:LNGOil and Gas

Cheniere Energy Expands Corpus Christi LNG As Valuation Shows Upside Potential

Cheniere Energy (NYSE:LNG) secured key U.S. regulatory approvals to expand LNG export capacity at its Corpus Christi facility. The U.S. Department of Energy authorized additional LNG exports, supporting the company’s plans for higher volumes. Construction is progressing on new liquefaction trains, which are intended to increase output from the Corpus Christi site. Cheniere Energy is a major U.S. LNG exporter, and Corpus Christi is one of its core hubs for supplying global buyers. The latest...
NYSE:DLX
NYSE:DLXCommercial Services

How Investors May Respond To Deluxe (DLX) Pivot Toward Data Solutions And Recurring Tech Revenues

In recent months, Deluxe has drawn renewed attention as its Data Solutions business benefits from accelerating adoption of digital operations by financial institutions and small and medium-sized enterprises. This shift highlights the company’s growing exposure to higher-quality, recurring technology revenues while its traditional print products remain under pressure from digital alternatives. We’ll now examine how the strong momentum in Deluxe’s Data Solutions segment may reshape the...
NYSE:NMM
NYSE:NMMShipping

Does Navios Maritime Partners' (NMM) Bigger Payout and Buyback Mark a Shift in Capital Priorities?

In February 2026, Navios Maritime Partners L.P. reported fourth-quarter 2025 results showing higher sales of US$365.55 million and net income of US$117.33 million year over year, alongside a 20% increase in its quarterly distribution to US$0.06 per unit and completion of a buyback covering 5.45% of its units. While full-year 2025 net income of US$285.33 million and earnings per unit eased compared with the prior year, the combination of stronger quarterly performance, higher distributions,...
NasdaqGS:DNLI
NasdaqGS:DNLIBiotechs

Assessing Denali Therapeutics (DNLI) Valuation After Wider Losses And New Shelf Registration

Why Denali Therapeutics Stock Is Back in Focus Denali Therapeutics (DNLI) is drawing fresh attention after reporting a wider net loss for the fourth quarter and full year, along with a new common stock shelf registration that signals possible future share issuance. See our latest analysis for Denali Therapeutics. At a share price of US$21.18, Denali’s short term momentum has been mixed, with a 4.9% 7 day share price return alongside a 16.63% 90 day share price return and a 30.18% year to date...
NYSE:CSR
NYSE:CSRResidential REITs

A Look At Centerspace (CSR) Valuation After Earnings Update And Dividend Reaffirmation

Centerspace (CSR) drew fresh attention after releasing fourth quarter and full year 2025 results, issuing 2026 earnings guidance that points to a net loss, and reaffirming its quarterly dividend payout. See our latest analysis for Centerspace. The latest earnings update and guidance arrived after a stretch where the 1 year total shareholder return was roughly flat at 0.05%, even as the share price return year to date declined 6.08%. This hints that momentum has softened despite dividends...
NYSE:POR
NYSE:PORElectric Utilities

Is Portland General Electric’s 2025 Results and US$480 Million Equity Raise Altering The Investment Case For Portland General Electric (POR)?

In February 2026, Portland General Electric reported full-year 2025 revenue of US$3,576 million and net income of US$306 million, while also disclosing lower earnings per share than the prior year. On the same day, the company completed a roughly US$480 million follow-on common stock offering, signaling a major capital raise that meaningfully alters its equity base and funding mix. We’ll now examine how this substantial equity issuance may influence Portland General Electric’s investment...
NYSE:DQ
NYSE:DQSemiconductor

Assessing Daqo New Energy (DQ) Valuation After Q4 2025 Results And 2026 Production Guidance

Daqo New Energy (DQ) stock is back in focus after the company released Q4 2025 results alongside fresh 2026 production guidance, combining its first positive EBITDA in six quarters with continued net losses. See our latest analysis for Daqo New Energy. At a share price of US$24.12, Daqo New Energy has a 1 year total shareholder return of 19.11%. However, the 3 year and 5 year total shareholder returns of 53.63% and 69.84% declines show that longer term momentum has been weak, despite the...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

Innoviva’s 2025 Earnings and NUZOLVENCE Launch Might Change The Case For Investing In Innoviva (INVA)

Innoviva, Inc. recently reported fourth-quarter 2025 revenue of US$114.61 million and net income of US$164.15 million, capping a full year in which revenue reached US$411.33 million and net income climbed to US$271.17 million. These results highlight the growing weight of the Innoviva Specialty Therapeutics platform in the business, alongside the U.S. FDA approval of NUZOLVENCE®, which together reinforce the company’s shift from a royalty-focused model toward a broader commercial portfolio...